Oxydrol Tablets
Oxydrol Tablets British Dragon — Overview
Oxydrol Tablets deliver oxymetholone at 50 mg per tablet — the compound known under the brand name Anadrol and consistently documented as the most potent oral mass-building AAS available. At 50 mg/day, oxymetholone produces weight gains in the range of 5–10 kg within the first 3–4 weeks of a cycle; at 100 mg/day, these gains accelerate further. A significant portion of early weight is water and glycogen — retained through pronounced estrogenic activity and glycogen supercompensation — but the underlying lean mass accrual is also genuinely high relative to any other oral compound. Strength increases are rapid and dramatic, making oxymetholone a mainstay in powerlifting and strongman cycle protocols.
Oxymetholone's pharmacology includes a feature that distinguishes it from every other common oral AAS: it produces strong estrogenic effects despite not undergoing aromatase-mediated conversion to estradiol. The mechanism is not fully resolved but likely involves direct partial agonism of estrogen receptors by oxymetholone or its metabolites. The practical consequence is significant — aromatase inhibitors (anastrozole, exemestane) do not reliably control oxymetholone's estrogenic activity because the aromatase pathway is not involved. SERM-based estrogen management is the appropriate approach for oxymetholone-specific gynecomastia risk. Steroid Warehouse carries Oxydrol as part of the British Dragon advanced oral lineup for experienced users running mass cycles.
About the Compound
Oxymetholone is a 17α-methylated dihydrotestosterone derivative with a 2-hydroxymethylene group added at the C2 position of the A-ring. The 17α-methyl group provides oral bioavailability at the cost of the highest hepatotoxicity in the standard oral AAS class — more pronounced than methandienone, oxandrolone, or stanozolol at any comparable dose. The C2 modification preserves anabolic activity in muscle tissue by protecting against 3α-hydroxysteroid dehydrogenase inactivation, similar to the mechanism in oxandrolone but via a different structural solution.
The defining pharmacological puzzle of oxymetholone is its estrogenic activity in the absence of aromatization. Oxymetholone is not a substrate for the aromatase enzyme — it does not convert to estradiol or any known estradiol derivative via the aromatase pathway. Yet it produces estrogenic effects — water retention, gynecomastia risk, and elevated sensitivity to estrogen-related side effects — more strongly than most aromatizing AAS at comparable doses. The proposed mechanisms include direct partial agonist activity at the estrogen receptor by oxymetholone itself or by 5β-reduction metabolites; none has been conclusively confirmed in the literature. The practical implication is well-established regardless of mechanism: aromatase inhibitors block the aromatase enzyme and therefore have little or no effect on oxymetholone's intrinsic estrogenic activity. SERMs (tamoxifen, clomiphene) act at the estrogen receptor level and provide meaningful protection against gynecomastia during oxymetholone use.
What Oxymetholone Does
Oxymetholone's output at 50 mg/day is qualitatively distinct from any other oral AAS — the speed and magnitude of its mass and strength effects are in a different category from methandienone, oxandrolone, or stanozolol at standard doses.
- Rapid and extreme mass gains — weight gains of 5–10 kg within 3–4 weeks at 50–100 mg/day are well-documented and routinely experienced. A substantial fraction — often 40–60% — consists of water and glycogen retained through estrogenic activity and glycogen supercompensation driven by significantly enhanced glycogenolysis. The remaining lean mass component is also large in absolute terms: 3–5 kg of genuine muscle tissue in 4 weeks is a reasonable expectation, exceeding the lean mass accrual rate of most other oral AAS at any dose.
- Strength increases — fastest of any oral AAS — the combination of mass loading on the musculoskeletal system, glycogen supercompensation, and androgen receptor-mediated contractile protein synthesis produces strength gains that manifest within the first week of use. Most users report meaningful strength increases by day 5–7 at 50 mg/day. At 100 mg/day, the strength effect is among the most pronounced achievable with any oral compound. This profile makes oxymetholone a long-standing fixture in powerlifting and strongman pre-competition cycles.
- Appetite stimulation — oxymetholone produces a distinct appetite-stimulating effect that is not shared to the same degree by other oral AAS. Users who struggle to consume adequate calories for mass-building find this property practically useful — the compound removes a significant barrier to caloric surplus. At 100 mg/day, some users report GI discomfort (nausea, bloating) that partially offsets the appetite effect; at 50 mg/day, appetite stimulation typically occurs without significant GI disruption.
- Erythropoiesis stimulation — significant hematocrit rise — oxymetholone's erythropoietic effect is more pronounced than most other oral AAS. The clinical use of oxymetholone in aplastic anemia treatment is based directly on this property. In athletic use, it produces meaningful hematocrit increases within 2–3 weeks that require monitoring — elevated hematocrit contributes to blood viscosity and cardiovascular risk.
Who It Is For
Oxydrol is appropriate for experienced AAS users who have prior cycle experience with both oral and injectable compounds, have bloodwork baselines established, and have a specific rationale for the most aggressive oral mass-building approach available in the British Dragon lineup.
- Advanced bodybuilders running maximum mass cycles — users who have run multiple cycles and need the highest-output oral phase available. Oxymetholone at 50–100 mg/day as a 4-week kickstart alongside a testosterone base delivers the fastest possible mass and strength onset while long-ester injectables build to working levels. Experienced users accept the water retention and manage the estrogenic load with tamoxifen; the mass and strength output at this phase is unmatched by any oral alternative.
- Powerlifters and strength-sport athletes at maximum output — for athletes in weight-classified strength sports where bodyweight gain is permitted or irrelevant, oxymetholone's pre-competition strength peak is unmatched in the oral class. The glycogen supercompensation and rapid strength progression in weeks 1–4 produce peak output aligned with a competition timeline when the cycle is planned around it.
- Hardgainers with established AAS experience — users who struggle with appetite and caloric intake for mass-building benefit from the appetite-stimulating effect at 50 mg/day alongside the anabolic output. The combination addresses both the stimulus (androgen receptor activation, nitrogen retention) and the substrate supply (appetite-driven caloric surplus) simultaneously.
Choose something else when: the user has not previously run an injectable testosterone cycle — oxymetholone's hepatotoxicity and estrogenic management complexity require prior cycle experience and established bloodwork baselines. Methanabol 10 is the appropriate introduction to oral mass builders. When lean gains are the objective rather than maximum mass, oxymetholone's pronounced water retention is counterproductive — Oxanabol Tablets BD provides anabolic support without the estrogenic load.
Oxydrol vs Alternatives
| Compound | Key Differences | Choose Oxydrol When | Choose Alternative When |
|---|---|---|---|
| Oxydrol Tablets British Dragon |
Oxymetholone 50 mg/tab; fastest and largest mass gains in the oral AAS class; non-aromatizing but strongly estrogenic — SERMs required; highest hepatotoxicity; appetite stimulation; significant hematocrit increase; 4 weeks max at this dose | Maximum oral mass and strength output; experienced users with bloodwork baselines; powerlifting strength peak; hardgainer protocol | — |
| Methanabol 50 British Dragon |
Methandienone 50 mg/tab; also a rapid oral mass builder; aromatizes directly — AI-manageable estrogenic effects; mass and water retention significant but less extreme than oxymetholone; 4–6 week cycle; lower hepatotoxicity than oxymetholone; more responsive to anastrozole for E2 control | Strong oral mass gains with AI-manageable estrogen control; prior oxymetholone experience not required; estrogen response is predictable | Maximum mass output regardless of water; appetite stimulation needed; most aggressive oral protocol → Oxydrol |
| Decabol 250 British Dragon |
Nandrolone decanoate 250 mg/ml; injectable; slow-building lean mass over 10–16 weeks; low aromatization; mild androgenicity; no acute hepatic burden; adds quality mass without the water spike of oxymetholone; requires 10–14 week run minimum for full effect; prolactin management needed | Slower, higher-quality mass gain prioritized over speed; hepatic concerns rule out oral AAS; longer cycle planned | Fast onset mass is essential; oral-only protocol needed; maximum 4–6 week window → Oxydrol |
| Boldabol Forte British Dragon |
Boldenone undecylenate; injectable; lean, dry mass gains over 12–16 weeks; low aromatization; minimal water retention; significant appetite stimulation (shared feature with oxymetholone); no hepatic burden; gradual quality gains rather than rapid water-assisted mass | Appetite stimulation needed alongside lean mass gains; dry, vascular bulk preferred; long cycle planned without oral hepatic burden | Rapid mass within 4 weeks; oral format; maximum weight gain speed → Oxydrol |
Combinations
| Goal | Stack | Why It Works |
|---|---|---|
| Maximum mass cycle kickstart | Oxydrol (50 mg/day, weeks 1–4) + Testabol Enanthate BD (500–600 mg/wk, weeks 1–14) + Decabol 250 BD (400 mg/wk, weeks 1–14) + Anastrozole BD (0.5 mg EOD for testosterone component) + Tamoxifen BD (20 mg/day throughout oral window) + Liv52 (weeks 1–4) | The archetypal advanced mass cycle: oxymetholone provides the fastest possible mass and strength onset while testosterone enanthate and nandrolone build to working levels. Anastrozole manages testosterone's E2; tamoxifen manages oxymetholone's receptor-level estrogenic activity — both are needed simultaneously and serve different mechanisms. After week 4, Oxydrol is discontinued; the injectable base continues. Nandrolone's prolactin-elevating potential should be monitored from week 6 onward. |
| Powerlifting strength peak | Oxydrol (50–100 mg/day, weeks 1–4) + Testabol Propionate BD (150 mg EOD, weeks 1–8) + Anastrozole BD (0.5 mg EOD) + Tamoxifen BD (20 mg/day, weeks 1–4) + Liv52 (weeks 1–4) | Testabol Propionate provides a fast-onset testosterone base matched to the oral's timeline — no ester lag means the injectable and oral reach working levels at the same time. The combined strength effect of oxymetholone (glycogen supercompensation, mass loading) and propionate (androgen receptor activation, neural drive) is maximally concentrated in the 4-week window. Dual estrogen management (AI for propionate, tamoxifen for oxymetholone) is essential at these combined doses. |
| Advanced bulk — oral window on a long base | Oxydrol (50 mg/day, weeks 1–4) + Boldabol Forte BD (600 mg/wk, weeks 1–16) + Anastrozole BD (0.25 mg EOD, reduced post-week 4) + Tamoxifen BD (20 mg/day, weeks 1–4) + Liv52 (weeks 1–4) | Boldabol Forte builds lean mass slowly with minimal aromatization — a dry long-cycle injectable. Adding a 4-week Oxydrol front-load injects rapid mass and strength into the early phase while boldenone builds to effective plasma levels. After week 4, oxymetholone is discontinued and anastrozole can be reduced (boldenone's low aromatization doesn't require high AI support). The caloric demands of an Oxydrol + boldenone phase are significant — appetite stimulation from both compounds supports the required surplus. |
Side Effects & Management
| What May Occur | Background | How to Handle It |
|---|---|---|
| Estrogenic effects — water retention, gynecomastia, blood pressure | Oxymetholone produces pronounced estrogenic effects without aromatization. Water retention of 5–10 kg in 4 weeks is common. Gynecomastia risk is significant and is not adequately managed by aromatase inhibitors alone — because aromatase is not the source. Blood pressure elevation driven by rapid fluid volume expansion is the most immediate cardiovascular concern and can develop within the first 2 weeks at 50 mg/day. | For gynecomastia protection: Tamoxifen BD 20 mg/day throughout the entire oral window — this is the primary estrogen management tool for oxymetholone's receptor-level estrogenic activity. For testosterone component's E2 (when stacked): Anastrozole BD. Blood pressure: Amlip (amlodipine) if readings exceed 130/80 mmHg on consecutive daily checks — monitor from week 1. |
| Hepatotoxicity — highest in the oral AAS class | Oxymetholone produces the most significant hepatic enzyme elevation of any standard oral AAS. Clinical data in patient populations at 1–5 mg/kg/day show that ALT/AST elevation is common and dose-dependent. In athletic use at 50–100 mg/day, liver enzyme rises are expected and pronounced. A 4-week cycle limit is the standard protocol for this compound — not a conservative guideline but a clinically appropriate ceiling given the hepatic burden rate. Extending to 5–6 weeks requires strict mid-cycle liver monitoring and is only defensible if enzymes at week 3 are within acceptable range. | Liver support from day one through the entire oral window: Liv52. Mandatory liver panel at week 2 — earlier than for most other oral AAS because oxymetholone's hepatic burden accumulates faster. Above 3× ULN: reduce dose. Above 5× ULN: discontinue immediately. No alcohol under any circumstances. |
| Hematocrit elevation | Oxymetholone's erythropoietic effect is more pronounced than other standard oral AAS — a property exploited in its clinical application for anemia. In a 4-week athletic cycle, hematocrit can rise from baseline values of 44–46% to 50–54%, particularly when combined with testosterone. Elevated hematocrit increases blood viscosity and raises cardiovascular risk, especially in the presence of oxymetholone-driven blood pressure elevation. | Hematocrit at baseline and week 2 (earlier check warranted at this dose). Above 54%: discontinue oxymetholone immediately. Between 50–54%: increase hydration, reduce dose, and recheck within 7 days. Adequate daily fluid intake throughout the cycle is essential. |
| Lipid disruption — HDL suppression, LDL elevation | Like all 17α-alkylated oral AAS, oxymetholone suppresses HDL and elevates LDL. The lipid impact at 50–100 mg/day is among the most pronounced in the oral class, compounding the cardiovascular concerns from elevated blood pressure and hematocrit. The combined lipid, pressure, and hematocrit risk profile at full oxymetholone doses is why cardiac risk monitoring is more intensive for this compound than for any other oral AAS. | Lipid panel at baseline and week 2. LDL above 130 mg/dL: Atorlip (atorvastatin). Omega-3 and reduced saturated fat intake throughout the cycle. Consider the combined cardiovascular picture — lipids, blood pressure, and hematocrit together determine overall risk, not any one marker in isolation. |
| Androgenic effects — acne, hair loss | Despite being a DHT-derivative, oxymetholone's androgenicity in skin tissue is moderated by its structural modifications. Acne is common but less universally severe than with stanozolol or fluoxymesterone; androgenetic hair loss acceleration occurs in predisposed users. At 50 mg/day, androgenic sides are typically manageable; at 100 mg/day, androgenic burden increases proportionally. | Persistent cystic acne: Isotroin (isotretinoin). Hair loss: dose is the only structural variable — no topical intervention addresses the androgenic root cause. |
| HPG axis suppression | Complete LH and FSH suppression at any meaningful oxymetholone dose. Always run with a testosterone base to cover the hypogonadal gap created by suppression. Without exogenous testosterone, endogenous testosterone is fully suppressed within the first 1–2 weeks, producing androgenic deficit symptoms rapidly. | Always stack with a testosterone base. PCT begins after the injectable base clears — not 3–5 days after the last tablet, unless oxymetholone was run as a standalone oral. |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| ALT / AST (liver enzymes) | Baseline; week 2 (mandatory — earlier than other oral AAS); end of cycle; 4 weeks post-cycle | Within 2× ULN during use. At oxymetholone doses, 2–3× ULN is common; above 3× ULN: reduce to 50 mg if running 100 mg, or discontinue at 50 mg. Above 5× ULN: stop immediately. Confirm baseline recovery 4 weeks post-cycle; persistent elevation requires further evaluation. |
| Hematocrit / CBC | Baseline; week 2; week 4 if continuing | Below 52% during use; below 54% absolute limit. Oxymetholone's erythropoietic effect is the fastest-acting of standard oral AAS — the week 2 check is not precautionary, it is clinically indicated. Above 54%: stop immediately. |
| Blood pressure | Every 3–4 days during the oral window | Below 130/80 mmHg. At oxymetholone, rapid fluid volume expansion from non-aromatase estrogenic activity can drive pressure up within days. Daily or every-other-day monitoring in the first 2 weeks is appropriate. If readings exceed 140/90 on two consecutive checks: start Amlip and reduce oxymetholone dose. |
| Lipid panel (HDL / LDL) | Baseline; week 2; 6 weeks post-cycle | HDL above 35 mg/dL; LDL below 130 mg/dL. At full oxymetholone doses, lipid deviation from baseline is rapid — earlier detection at week 2 allows earlier Atorlip intervention if needed. Confirm lipid recovery at 6 weeks post-cycle. |
| Estradiol (E2) | Baseline; week 2 | Target 20–40 pg/mL for the testosterone-aromatization component. Note: E2 measurement in an oxymetholone cycle reflects the testosterone-derived aromatization only — oxymetholone's own estrogenic activity does not show as elevated E2 on standard assay. A normal E2 reading does not mean estrogenic effects from oxymetholone are absent or well-controlled. |
| LH + FSH | Baseline; 4 weeks post-PCT | Confirm gonadotropin recovery to pre-cycle baseline. Full HPG axis recovery after an advanced injectable + oxymetholone cycle with proper PCT typically takes 4–8 weeks from the end of SERMs. |
PCT — Post-Cycle Therapy
PCT timing is governed entirely by the injectable base clearance. Oxymetholone itself has a short half-life (~8–16 hours) and clears within 1–2 days of the last tablet — but if used as a kickstart on a testosterone enanthate cycle, the enanthate's 2-week clearance window determines PCT start. Beginning Clomiphene and Tamoxifen while long-ester testosterone is still active significantly reduces PCT effectiveness.
| Product | Role |
|---|---|
| Clomiphene Tablets BD | 50 mg/day weeks 1–2, then 25 mg/day weeks 3–4. LH/FSH stimulant. After an advanced cycle at oxymetholone + injectable doses, the full 4-week protocol is standard. Post-PCT bloodwork at week 8 confirms recovery; if LH/FSH remain suppressed, extend Clomiphene for another 2 weeks before re-evaluating. |
| Tamoxifen Tablets BD | 20 mg/day weeks 1–2, then 10 mg/day weeks 3–4. Hypothalamic SERM — restores GnRH pulse frequency. Run concurrently with Clomiphene. Note that tamoxifen was already used during the cycle for gynecomastia protection — transitioning directly from the cycle dose (20 mg/day) into PCT dosing at the same level requires no adjustment in the first week of PCT. |
Practical Summary
- Tamoxifen is not optional — it runs with the cycle, not just at PCT: oxymetholone's estrogenic mechanism bypasses aromatase. Anastrozole alone does not protect against gynecomastia from oxymetholone. Tamoxifen 20 mg/day must run alongside the oral window from day one. This is the single most important protocol point for this compound and the most commonly mismanaged.
- Week 2 bloodwork is the monitoring checkpoint, not week 3–4: liver enzymes, hematocrit, and blood pressure all rise faster on oxymetholone than on other oral AAS. By week 3, hepatic and hematocrit changes may already be at levels requiring action. Week 2 bloodwork provides enough lead time to course-correct within the 4-week cycle window.
- 4-week limit is pharmacologically grounded, not conservative: oxymetholone's hepatic burden rate per day is the highest in the oral AAS class. A 4-week window with proper monitoring is appropriate; extending to 5–6 weeks is not a routine upgrade — it requires mid-cycle liver panel confirmation at week 3 and is not appropriate for first-time oxymetholone users.
- Blood pressure requires near-daily monitoring in weeks 1–2: the estrogenic-driven fluid volume expansion at oxymetholone doses can push blood pressure from normal to 140/90+ within 10–14 days. Every-other-day BP tracking in the first two weeks is not excessive — it is appropriate to the pharmacological load. Start Amlip at the first sign of sustained elevation rather than waiting for a second bloodwork visit.
- Appetite stimulation is a functional feature — plan caloric intake around it: the increased appetite at 50 mg/day is a practical asset for mass cycles. Prepare food availability and meal frequency to take advantage of the appetite window, particularly in the first 2 weeks when the effect is most pronounced.
- PCT start is the injectable ester clearance date — not 2 days after the last tablet: oxymetholone clears in 1–2 days. If running it as a kickstart with testosterone enanthate, PCT begins ~2 weeks after the last injection. Starting SERMs early does not accelerate recovery — it wastes them and leaves the window incorrectly managed.
Oxydrol remains the highest-output oral AAS in the British Dragon catalog — a compound with a specific, well-defined role in advanced mass cycles, powerlifting strength protocols, and situations where the speed and magnitude of mass gains take priority over the complexity of management. Its pharmacology is uniquely demanding: non-aromatizing yet estrogenic, maximally hepatotoxic, and requiring simultaneous AI and SERM management when stacked with testosterone. Used with proper monitoring and experience, it delivers results no other oral compound matches. steroidwarehouse.com carries the full British Dragon oral range for every experience level and cycle goal.
References
| Source | Description | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, establishing the anabolic effects of supraphysiologic testosterone administration | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, oral and injectable forms, adverse effect profiles, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone, dihydrotestosterone, androgen receptor signaling, HPG-axis regulation, synthetic androgen pharmacology, aromatization, and endocrine suppression associated with exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| British Journal of Pharmacology / PubMed | Kicman AT 2008 — comprehensive review of anabolic-androgenic steroid pharmacology; covers androgen receptor binding, steroid metabolism, structural modification, ester pharmacokinetics, anabolic and androgenic mechanisms, detection methods, and adverse effects associated with AAS use | Kicman AT (2008) ↗ |
| Sports Medicine / PubMed | Hartgens F & Kuipers H 2004 — review of androgenic-anabolic steroid effects in athletes; covers strength and bodyweight changes, body composition, erythropoiesis, lipid profiles, cardiovascular effects, endocrine suppression, hepatic effects, and psychological considerations | Hartgens F & Kuipers H (2004) ↗ |
| Seminars in Liver Disease / PubMed | Ishak KG & Zimmerman HJ 1987 — review of hepatotoxic effects associated with anabolic-androgenic steroids; covers cholestatic liver injury, peliosis hepatis, hepatic adenoma, and hepatocellular carcinoma, with strongest relevance to 17α-alkylated oral anabolic steroids such as oxymetholone | Ishak KG & Zimmerman HJ (1987) ↗ |
What is Oxydrol Tablets used for?
Oxydrol Tablets are used for rapid muscle mass and strength gains; see What is Oxydrol Tablets Used for. It's potent—consult professionals for safe use.
Does Oxydrol Tablets aromatize?
No, Oxydrol Tablets do not aromatize; see Does Oxydrol Tablets Aromatize. It has progestogenic effects—consult professionals for guidance.
Are Oxydrol Tablets safe?
They can be safe with oversight, but risks include liver toxicity; see Are Oxydrol Tablets Safe. Consult professionals for monitoring.
How should I use Oxydrol Tablets?
Use 50-100 mg/day, split into 2 doses for 4-6 weeks; see How Should I Use Oxydrol Tablets. Start low—consult professionals for dosing.
What are the main benefits of Oxydrol Tablets?
Commonly reported benefits include rapid muscle mass gains, enhanced strength, improved recovery, increased workout intensity, and greater muscle fullness.
What are the possible side effects of Oxydrol Tablets?
Potential side effects may include water retention, elevated blood pressure, acne, liver stress, changes in cholesterol levels, and suppression of natural testosterone production.
What makes Oxydrol Tablets different from other oral anabolic steroids?
Oxydrol Tablets are known for their powerful anabolic effects and reputation for producing rapid increases in muscle size, strength, and overall training performance.
How long does it take to notice effects from Oxydrol Tablets?
As an oral compound, Oxydrol Tablets are often associated with a rapid onset, with users commonly reporting increases in strength, muscle fullness, and training performance within the first few weeks.
Related Products
